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treatment with decitabine and TSA increased docetaxel sensitiv-
ity in MCF-7 and MDA-MB-231 cells (P < 0.05). An array of 84 genes
identified 5 genes decreased in resistant cells whose expression
was upregulated after decitabine and TSA treatment (P < 0.05).
Western analysis confirmed expression changes in only one gene,
SERPINE1, in docetaxel-resistant cells.
Conclusions: Docetaxel resistance is associated with changes in
the DNAmethylation machinery. Inhibiting DNAmethylation and
histone deacetylation, in combination, overcomes resistance of
breast cancer cells to docetaxel. Our findings indicate that
decreased SERPINE1 expression is associated with docetaxel
resistance.
doi:10.1016/j.ejcsup.2010.06.012
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The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a fre-
quently deregulated pathway in breast cancer (BC). Akt arguably
relays a plethora of extracellular signals to modulate diverse bio-
logic effects, including cell proliferation, growth, motility, and sur-
vival, downstream of PI3K activation. However, complexity and
diversity in the upstream/downstream arms of this pathway chal-
lenge considerably the clinical evolvement of effective therapies.
This study aims to study expressions of PIK3CA and phospho-
Akt1 (pAkt) in BC, with respect to proteins upstream/downstream
of Akt activation, clinicopathologic parameters, and disease out-
come. PIK3CA and pAkt (ser473) were evaluated by immunohisto-
chemistry on tissue microarrays containing 1202 early invasive
BC with long term follow-up.
In this study, pAktoverexpressionwasassociatedwithpatients’
age, estrogen and androgen receptors, cytokeratin (CK)18, CK19
and PTEN expression. Loss of pAkt was correlated with higher
grade, CK5/6, p53 and Ki-67 labelling index. Luminal-like tumours
displayedmore pAkt positivity than triple negative/basal-like sub-
types. However, pAkt overexpression was not associated with
breast cancer-specific (BCSS) or metastasis-free survival (MFS).
Four combinatorial phenotypes were identified based on PIK3CA
and pAkt expression, with considerable proportions being
PIK3CA/pAkt+ or PIK3CA+/pAkt. These phenotypes were signifi-
cantly associated with BCSS (p = 0.001) and MFS (p = 0.002).
Although pAKT is an oncogene that correlated with poor prog-
nostic variables, itwasnot aprognosticmarker. Combinatorial phe-
notypic groups of PIK3CA/pAkt denoted, at translational level,
functional complexity within the upstream and downstream net-
workofAktactivationwithsignificant impactonpatients’ outcome.
Thesefindingsmayhelpdevelopingadequate therapeutic regimens
against specific components of this key signalling pathway.
doi:10.1016/j.ejcsup.2010.06.013
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D-Glucuronyl C5-epimerase (GLCE) is one of the key enzymes
of the biosynthesis of heparan sulphate proteoglycans. Down-
regulation of GLCE expression in human breast tumours and can-
cer cell lines suggested a possible involvement of the gene in
breast carcinogenesis. To test the hypothesis, we ectopically
expressed GLCE in breast cancer cells MCF7 and showed that
re-expression of D-glucuronyl C5-epimerase significantly inhibited
proliferative activity of MCF7 cells according to CyQUANT NF Cell
Proliferation Assay and did not affect the viability of the cells in
Colony Formation Test. The antimitotic effect of D-glucuronyl C5-
epimerase in human breast cancer cells probably is realised via
the activation of tumour suppressor genes SYK (+8.1-fold), BRCA1
(+3.5-fold), p53 (+3.3-fold) and E2F1 (+3.00-fold) and change of a
balance of pro- and anti-apoptotic factors BCL2 (+4.2-fold), NFKB1
(+2.6-fold) and TNF (+4.6-fold) (PathFinder RT Profiler PCR Array).
Also, GLCE re-expression in MCF7 cells considerably changed
expression of some genes involved in angiogenesis (IL8, IFNB1,
TNF and TGFB1) and invasion/metastasis (SYK, NME1, S100A4)
suggesting a possible antimetastatic effect of GLCE in vivo.
In summary, the ability of the D-glucuronyl C5-epimerase to sup-
press proliferation of breast cancer cells through the affecting dif-
ferent key genes involved in cell cycle regulation, angiogenesis
and invasion/metastasis molecular pathways supposes the gene
as a new potential candidate for diagnosis and treatment of
breast cancer.
doi:10.1016/j.ejcsup.2010.06.014
O-14 EXPRESSION AND ACTIVATION OF Akt AND NFkB IN
BREAST CANCER PATIENTS
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Background: It is postulated that Akt activates the Nf-kB
pathway to promote tumour growth and survival in breast cancer
cells.
Material and methods: Tissue microarray technology was
employed to analyse tissue from 426 breast cancer patients.
Immunohistochemistry was performed using antibodies for pAkt
(phosphorylated at serine 473), NF- kB and pNFkappaB (phosphor-
ylated at serine 536). Expression was assessed using the weighted
histoscore method by two independent scorers.
Results: Median age was 62 years, median tumour size was
20 mm, 48% were pathologically graded G2 and 31% G3 and 48%
were lymph node positive. Ninety-eight patients had unilateral
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